|
Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >
Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin : A Novel Case Report
| Title: | Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin : A Novel Case Report |
| Authors: | Saito, Yoshitaka Browse this author →KAKEN DB | | Takekuma, Yoh Browse this author →KAKEN DB | | Oshino, Tomohiro Browse this author | | Sugawara, Mitsuru Browse this author →KAKEN DB |
| Keywords: | Chemotherapy-induced peripheral neuropathy | | Mirogabalin | | Duloxetine | | Eribulin |
| Issue Date: | 10-Jun-2022 |
| Publisher: | Karger |
| Journal Title: | Case reports in oncology |
| Volume: | 15 |
| Issue: | 2 |
| Start Page: | 606 |
| End Page: | 610 |
| Publisher DOI: | 10.1159/000525059 |
| Abstract: | Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most severe complications associated with chemotherapy for breast cancer. We encountered a case in which mirogabalin initially ameliorated, and additional duloxetine further attenuated eribulin-induced CIPN. Herein, we report its management. A 53-year-old woman received eribulin treatment as third-line chemotherapy for recurrent breast cancer. She experienced grade 2 CIPN with adjuvant docetaxel and cyclophosphamide treatment (worst numeric rating scale (NRS) 6/10 for numbness and 6/10 for pain) and had baseline grade 1 symptoms only in the hands (NRS 1/10 for each). CIPN in the hands and feet worsened to NRS 3/10 on day 1 of cycle 4. Mirogabalin (5 mg twice daily) was initiated, resulting in stable symptoms for approximately 6 weeks with grade 1 somnolence and heaviness of the head. The dosage was increased with careful attention to adverse effects to 22.5 mg per day, and the NRS was reduced from 5/10 to 3/10 for numbness and from 8/10 to 5/10 for pain. We administered duloxetine 20 mg with domperidone (10 mg three times a day) for further pain attenuation on day 1 of cycle 15, decreasing the NRS to 1/10 for numbness and 3/10 for pain. Duloxetine was increased due to CIPN degradation (NRS 3/10 and 5/10), resulting in a significant pain attenuation to 1/10. As the CIPN-attenuating mechanisms of mirogabalin and duloxetine are different, we consider that the additive and synergetic effects of this combination affected the results. Combination therapy with these drugs may be a promising strategy. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/87172 |
| Appears in Collections: | 薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
